ABSTRACT OBJECTIVES This study sought to review the outcomes for the Sapien and Sapien XT valves (Edwards Lifesciences, Irvine, California) for percutaneous pulmonary valve implantation (PPVI).
experience with the Sapien system in this setting is limited to 1 prospective, nonrandomized, multicenter study (5) and 3 small case series (6) (7) (8) , with a total of 72 patients ( Table 1) . Use of the Sapien valve has afforded treatment of larger conduits and, in select cases, native outflow tracts (9, 10) . There are little long-term data, however, with most studies reporting up to 6 months follow-up only. We describe our experience with the Sapien system in the pulmonary position. PROCEDURE. All procedures were performed under general anesthesia with fluoroscopic guidance.
Transesophageal echocardiography was not used.
Prophylactic antibiotics were administered at the time of procedure before valve implantation. Large sheath access site was via the femoral vein in 22 patients and jugular vein in 3 patients. Anticoagulation was achieved with intravenous heparin (100 U/kg to achieve and activated clotting time of longer than 250 s). Pre-stenting was performed in all cases and mostly (96%) at the time of valve implantation. The Wilson et al.
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Edwards Sapien transcatheter heart valve was avail- Technical success was defined as deployment of the valve to the target area with removal of the delivery catheter from the body without significant residual RVOT dysfunction (defined as mean RV-to-PA gradient <15 mm Hg and pulmonary regurgitation severity mild or less).
Need for reintervention during follow-up was ascertained. All continuous variables were tested for normality before data analysis, and paired t test was used for comparison of mean values pre-versus immediate post-procedure. Due to the differences in follow-up duration, the annual rate of change was calculated and analyzed using 1-sample test. Values of p < 0.05 were considered statistically significant for all tests.
RESULTS
PPVI using the Sapien system was attempted in 25
patients. Baseline characteristics are presented in Table 2 . Procedural data are presented in Table 3 . Valve sizes used were 23 mm (n ¼ 8), 26 mm (n ¼ 15), and 29 mm (n ¼ 2). The Sapien XT valve was used in 4 cases, the first being delivered via a Glenn shunt ( Figure 1 ).
The mean number of stents used for pre-stenting Mild hemoptysis occurred in another patient, which did not require treatment.
Hemodynamic data pre and post PPVI are presented in Table 4 . The valve orientation in this case was the same as is used in the aortic position, but the realignment maneuver had to be performed within the eSheath, which was more difficult to achieve than realignment within the inferior vena cava. When delivered via the RVOT (from the jugular or femoral veins), the Sapien XT valve needs to be mounted in the opposite direction, and a theoretical concern existed initially regarding leaflet damage due to involution during the realignment maneuver. Subsequent to our first case severe aortic stenosis, where valve durability does not appear to be an issue (13, 14) .
Valve fractures were not seen in our series but were not systemically searched for. There are no reports to date of fractures involving the Sapien prosthesis in the aortic or pulmonic position. There were no confirmed cases of endocarditis in our series.
STUDY LIMITATIONS. This is a small, observational study, and larger studies with longer follow-up duration are warranted to confirm the durability and safety of the Sapien system in the pulmonic position. Ideally, a standardized follow-up protocol would be employed to track functional status and valve function. 
